Pluvicto, a prostate cancer drug, has gained expanded approval that triples the number of patients with metastatic disease ...

Novartis’ radioligand therapy Lu-PSMA-617 has met its target in prostate cancer, as its $2.1 billion acquisition of specialist pharma Endocyte looks to have been justified. The big Swiss ...

PSMA-targeted radioligand therapies (PRLT) for metastatic castration-resistant prostate cancer (mCRPC ... decline were not affected by cancer type, previous treatment, or combination therapies.

The sector has seen billions in merger and acquisition activity in recent years; a September 2024 analysis by Insight ...

Metastatic castration-resistant prostate cancer (mCRPC) treatment can involves chemotherapy, radiation, and more. Find the ...

In 2025, the therapeutic landscape for advanced prostate cancer in Germany is marked by remarkable progress—ranging from radioligand therapy to precision imaging and immunotherapy. This article ...

Guidelines created by a multi-disciplinary panel of specialists focus on implementation of novel treatments and technologies for which level 1 evidence is lacking.

Prostate cancer is a common type of cancer in males, but it is highly treatable in the early stages. It begins in the prostate gland, which sits between the penis and the bladder. Experts do not ...

Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have validated a test that can accurately predict which ...

The hope is the therapy can effectively target cancerous cells at relatively small doses while minimizing side effects.

But a new genetic test appears capable of sussing out which men are at greater risk of urinary side effects from radiation ...